CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


BiosensorsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug837 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 1.00

Correlated MeSH Terms (13)


Name (Synonyms) Correlation
D006470 Hemorrhage NIH 1.00
D006929 Hyperaldosteronism NIH 1.00
D014552 Urinary Tract Infections NIH 1.00
D000309 Adrenal Insufficiency NIH 1.00
D054559 Hyperphosphatemia NIH 1.00
D007008 Hypokalemia NIH 1.00
D001997 Bronchopulmonary Dysplasia NIH 1.00
D008595 Menorrhagia NIH 1.00
D006973 Hypertension NIH 0.45
D003141 Communicable Diseases NIH 0.12
D007239 Infection NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0000132 Menorrhagia HPO 1.00
HP:0002900 Hypokalemia HPO 1.00
HP:0000859 Hyperaldosteronism HPO 1.00
HP:0000846 Adrenal insufficiency HPO 1.00
HP:0000822 Hypertension HPO 0.71

There is one clinical trial.

Clinical Trials


1 Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study

Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. It is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment. The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up. Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study we will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).

NCT04335097 COVID 19 Device: Biosensors

Primary Outcomes

Description: Day during home isolation it was stopped due to hospitalization

Measure: Stop home isolation

Time: 1 to 21 days

Description: 5 or >3 for one organ system

Measure: NEWS score

Time: 1 to 21 days

Secondary Outcomes

Description: Relevant vital clinical findings

Measure: Clinic at hospitalization

Time: At admittance hospital

Description: Symptoms developed during home isolation

Measure: Symptoms developed

Time: Duration of home isolation

Description: Their description of vital sign development

Measure: Relative/peers evaluation of the patient

Time: Duration of home isolation

Description: Referred to ICU, intubated, length of stay

Measure: Serious of symptoms at admittance hospital

Time: Hospital stay


No related HPO nodes (Using clinical trials)